Member Info for Antha

Those are the covid-19 tests for their machines of which they can do up to 10,000 per machine per day. This rns is for their brand new 15 minute tests which we should now get impressive sales figures on a regular basis raising the sp each time. 12 months from now the sp will many multiples of today's price which is why I said it's a great long term hold.

Nice rise, remember this has hit 1200p in the past.

Next news I guess will hopefully be Directors buys.

Was anyone lucky enough to buy in the 7's first thing this morning, as usual I was asleep.

When the relending started RNS drops it will easily do 100% on the day.

Results and cash balance were much better than I was expecting, 2021 is going to be a good year for Amigo.

BPC, if it's a non duster and then possibly a farm-in next year then 50p is a distinct possibilty.
PRD, probably more long term but if the stars align correctly then 20p-30p.
AMGO, once lending restarts and the claims nonsence has finished I don't see why we can't see at least 50p within 12 months.

*massacre, rubbish spell check.

MTFB what a sorry tell that is/was, luckily got out at 7p after the ST Valetines massacare (95% drop in one day), my current picks are BPC, PRD and of course AMGO.

Currently has to be one of the most stable stocks going which is great for those that want to invest in an IHT portfolio.

FigTree, JB didn't let anyone down, he simply pumped and dumped all his stock at a far higher price than it is now, if people were silly enough to believe his tweets then more fool them, what JB did was unethical but perfectly legal.
For what it's worth I think the sp will be 15p plus by the new year.

90% is indeed excellent for the 1/2 + 1 doses but what most people are missing is that it is much easier to store, transport and administer than the others, no dry ice or special equipment needed. Vaccines normally take 5 years plus to get to this stage this has taken 8 months which is a huge achievement.

Group revenues lower as expected but recovering well, increased headcount as the company is expanding which is an amazing achievement during this pandemic, I especially liked these two paragraphs regarding new tests.

1.5 COVID-19 Products
Towards the end of H1 FY21 we launched two automated immunoassays for the detection of SARS-CoV2 IgG and IgM antibodies, which can detect past infections as well as providing critical public health information. We also provided outsourced manufacturing services to The Binding Site (UK) for their ELISA-based SARS-CoV-2 antibody test. Revenue from COVID-19 products amounted to £0.4m during Q2 FY21.

With the potential arrival of SARS-CoV-2 vaccines, public health studies into the virus should increase as there will be a need to measure the success of the vaccination programmes. There should be a growing interest in monitoring the overall antibody level in a population to measure the attainment of a protective antibody level nationwide for achieving herd immunity. This could drive increased sales of our automated SARS-CoV2 antibody tests.

The above tests are used to confirm past infections. However currently the market focus is on testing to verify an active infection. Therefore, in conjunction with one of our partners, we are working on the development of a saliva-based rapid test for SARS-CoV-2 antigens. This manual test, which has the potential for self-administered use, would allow for immediate identification of individuals with an elevated amount of SARS-CoV-2 virus and be extremely helpful for curtailing the spread of the virus. In addition, it will overcome the shortcoming of presently used rapid tests based on nasopharyngeal swabs, which rely on sampling by professional staff only.

1.6 Assay Development and Product Registration
In Europe, in addition to the two automated SARS-Cov-2 tests we released the IDS Automated Cortisol assay, which rounds out our automated hypertension panel. We also entered the field of therapeutic drug monitoring, with a panel of four new tests co-developed with a partner. These are the first such automated tests on the market. They are used to monitor the efficacy of Infliximab (trade name Remicade) and Adalimumab (trade name Humira) which are antibody-based drugs used in the management of chronic inflammatory diseases.

In the US we achieved 510k approval for our BAP assay and expect to make the first sales of this key assay to a major US laboratory chain during H2 FY21.

Hate to say the tired old cliche but "I wouldn't want to be out of this over the weekend"

Never thought looking at a satellite image would be so much fun.

Thanks to everyone who made the sp drop as it allowed me to treble my holding at a price I didn't think I would see again.

In profit now but won't sell until at least 20p hopefully before Christmas.

I believe the all time high was over 1200p, the company is well under the radar at the moment which will change once it starts releasing covid test sales figures, think of it like NCYT six months ago :-)

Keeps going to nt for large quanties.

Bought a load today at 200p and will add more on any dips, I plan to keep them for the long term.
The reasons for buying, it's a very well run company, bod and ii's hold most of the shares with a small free float, huge cash pile to buy out rivals, they are well established in their market and they've started to roll out their own covid-19 tests.